Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase NA 2Phase 3 2Phase 1 2Phase 4 1Phase 1/2 1

Status

Completed 4Withdrawn 2Recruiting 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1

Conditions

Hearing Loss 1Ear Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 35Cisplatin 24fludarabine 23Radiotherapy 23Paclitaxel 21Carboplatin 20pembrolizumab 18Nivolumab 18Magnetic Resonance Spectroscopy 18Specimen Handling 17fludarabine phosphate 15Gemcitabine 15Biopsy 15Cytarabine 14Radiation 11Filgrastim 11Doxorubicin 11Docetaxel 11Dexamethasone 11Radiosurgery 10Granulocyte Colony-Stimulating Factor 10Etoposide 10Melphalan 9Ipilimumab 9venetoclax 8Rituximab 8Calcium Dobesilate 8trametinib 7ibrutinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × Saline Solution × Clear all
NCT03177252 2020-10-22

Scalp block

Washington University School of Medicine

Phase 1 Withdrawn
CNS

Brain Neoplasms

NCT00584155 2015-05-27

Protection From Cisplatin Ototoxicity by Lactated Ringers

University of Oklahoma

Phase 1 Withdrawn

Ear Neoplasms, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡